Ping Duan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ping Duan has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Chenchen Mao
Department of General Surgery First Affiliated Hospital Wenzhou Medical University Wenzhou Zhejiang 325000 China
1 shared publicationGangqiang Guo
Department of Microbiology and Immunology Institute of Molecular Virology and Immunology Institute of Tropical Medicine Wenzhou Medical University Wenzhou Zhejiang 325000 China
1 shared publicationJianfeng Xu
Department of General Surgery First Affiliated Hospital Wenzhou Medical University Wenzhou Zhejiang 325000 China
1 shared publicationJun Chen
Department of Microbiology and Immunology Institute of Molecular Virology and Immunology Institute of Tropical Medicine Wenzhou Medical University Wenzhou Zhejiang 325000 China
1 shared publicationLedan Wang
Department of Obstetrics and Gynecology Second Affiliated Hospital Wenzhou Medical University Wenzhou Zhejiang 325000 China
1 shared publicationRuanmin Zou
Department of Obstetrics and Gynecology First Affiliated Hospital Wenzhou Medical University Wenzhou Zhejiang 325000 China
1 shared publication
Latest Publications
- Open Access
- 15 January 2017
- Published by Wiley in Cancer Medicine
- Vol. 6 (2) , 471-482
Upregulation of long noncoding RNA TUG1 promotes cervical cancer cell proliferation and migration
Long noncoding RNA s (lnc RNA s), a novel class of transcripts that have critical roles in carcinogenesis and progression, have emerged as important gene expression modulators. Recent evidence indicates that lnc RNA taurine‐upregulated gene 1 ( TUG 1) functions as an oncogene in numerous types of human cancers. However, its function in the development of cervical cancer remains unknown. The aim of this research was to investigate the clinical significance and biological functions of TUG 1 in cervical cancer. TUG 1 was found to be significantly upregulated in cervical cancer tissues and four cervical cancer cell lines by quantitative real‐time polymerase chain reaction ( qRT ‐ PCR ). Elevated TUG 1 expression was correlated with larger tumor size, advanced international federation of gynecology and obstetrics ( FIGO ) stage, poor differentiation, and lymph node metastasis. Furthermore, knockdown of TUG 1 suppressed cell proliferation with activation of apoptosis, in part by regulating the expression of Bcl‐2 and caspase‐3. Silencing of TUG 1 inhibited cell migration and invasion via the progression of epithelial–mesenchymal transition ( EMT ). Taken together, our findings indicate that TUG 1 acts as an oncogene in cervical cancer and may represent a novel therapeutic target.
- 15 January 2017
- Published by Wiley in Cancer Medicine
- Vol. 6 (2) , 471-482
Open AccessUpregulation of long noncoding RNA TUG1 promotes cervical cancer cell proliferation and migration
Long noncoding RNA s (lnc RNA s), a novel class of transcripts that have critical roles in carcinogenesis and progression, have emerged as important gene expression modulators. Recent evidence indicates that lnc RNA taurine‐upregulated gene 1 ( TUG 1) functions as an oncogene in numerous types of human cancers. However, its function in the development of cervical cancer remains unknown. The aim of this research was to investigate the clinical significance and biological functions of TUG 1 in cervical cancer. TUG 1 was found to be significantly upregulated in cervical cancer tissues and four cervical cancer cell lines by quantitative real‐time polymerase chain reaction ( qRT ‐ PCR ). Elevated TUG 1 expression was correlated with larger tumor size, advanced international federation of gynecology and obstetrics ( FIGO ) stage, poor differentiation, and lymph node metastasis. Furthermore, knockdown of TUG 1 suppressed cell proliferation with activation of apoptosis, in part by regulating the expression of Bcl‐2 and caspase‐3. Silencing of TUG 1 inhibited cell migration and invasion via the progression of epithelial–mesenchymal transition ( EMT ). Taken together, our findings indicate that TUG 1 acts as an oncogene in cervical cancer and may represent a novel therapeutic target.